Asia Myelodysplastic Syndrome (MDS) Registry
ConditionMyelodysplastic Syndromes (MDS)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
Eligibility criteria
Qualifiers
Aged at least 18 years at initial diagnosis of MDS
Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
Aged at least 18 years at initial diagnosis of MDS; and
Disqualifiers
None
Trial design
Treatments tested in this trial
- Prescribed treatments for myelodysplastic syndromes (MDS)
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov